Home
>
National Drug Code (NDC)
>
JUVISYNC
JUVISYNC - 0006-0535-31 - (SITAGLIPTIN and SIMVASTATIN)
Drug Information of JUVISYNC
| Product NDC: | 0006-0535 |
| Proprietary Name: | JUVISYNC |
| Non Proprietary Name: | SITAGLIPTIN and SIMVASTATIN |
| Active Ingredient(s): | 20; 50 mg/1; mg/1 & nbsp; SITAGLIPTIN and SIMVASTATIN |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of JUVISYNC
| Product NDC: | 0006-0535 |
| Labeler Name: | Merck Sharp & Dohme Corp. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA202343 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20120918 |
Package Information of JUVISYNC
| Package NDC: | 0006-0535-31 |
| Package Description: | 30 TABLET, FILM COATED in 1 BOTTLE (0006-0535-31) |
NDC Information of JUVISYNC
| NDC Code | 0006-0535-31 |
| Proprietary Name | JUVISYNC |
| Package Description | 30 TABLET, FILM COATED in 1 BOTTLE (0006-0535-31) |
| Product NDC | 0006-0535 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | SITAGLIPTIN and SIMVASTATIN |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20120918 |
| Marketing Category Name | NDA |
| Labeler Name | Merck Sharp & Dohme Corp. |
| Substance Name | SIMVASTATIN; SITAGLIPTIN PHOSPHATE |
| Strength Number | 20; 50 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Dipeptidyl Peptidase 4 Inhibitor [EPC],Dipeptidyl Peptidase 4 Inhibitors [MoA],HMG-CoA Reductase Inhibitor [EPC],Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA] |
